NCT05021900View on ClinicalTrials.gov

Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions

Locally Advanced Breast CancerMetastatic Breast Cancer

Interventions

DRUG

Tenalisib 800mg

Tenalisib will be administered 800mg BID, orally

DRUG

Tenalisib 1200mg

Tenalisib will be administered 1200mg BID, orally

Trial Locations (3)

Unknown

High Technology Hospital Medcenter, Batumi

Simon Khechinashvili University Hospital, Tbilisi

0186

LLC Caucasus Medical Center, Tbilisi

All Listed Sponsors

lead

Rhizen Pharmaceuticals SA

INDUSTRY

NCT05021900 - Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter